- Open Access
Erratum to: Interleukin-6: a new therapeutic target
Arthritis Research & Therapy volume 8, Article number: 407 (2006)
- The original article was published in Arthritis Research & Therapy 2006 8:S5
Following the publication of the above article , we noticed that due to an administrative oversight the Competing interests section was incomplete and should read as follows:
JSS has received financial compensation from and served on advisory boards for Roche and is an investigator in clinical trials of tocilizumab. RNM has received consulting fees from Chugai; served on an ad hoc advisory board for Roche; and was responsible for the planning and preparation for publication of the Phase II European (CHARISMA) trial of tocilizumab with and without methotrexate. A patent for co-administration of methotrexate and tocilizumab for the treatment of rheumatoid arthritis, of which RNM is named as a co-inventor, has been applied for and fully assigned to Chugai.
Smolen JS, Maini RN: Interleukin-6: a new therapeutic target. Arthritis Res Ther. 2006, 8 (Suppl 2): S5-10.1186/ar1969.
The online version of the original article can be found at 10.1186/ar1969
About this article
Cite this article
Smolen, J.S., Maini, R.N. Erratum to: Interleukin-6: a new therapeutic target. Arthritis Res Ther 8, 407 (2006). https://doi.org/10.1186/ar2065